Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any neuronopathy, distal hereditary motor in which the cause of the disease is a mutation in the BSCL2 gene.
Features include always present findings: Decreased compound muscle action potential amplitude, Babinski sign, and Chaddock reflex. 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 4 | Decreased compound muscle action potential amplitude, Distal lower limb muscle weakness, Thenar muscle atrophy |
BSCL2 encodes BSCL2 lipid droplet biogenesis associated, seipin (398 aa). Plays a crucial role in the formation of lipid droplets (LDs) which are storage organelles at the center of lipid and energy homeostasis. Highest expression in Pituitary (297.7 TPM) and Testis (266.7 TPM).
Neuronopathy, distal hereditary motor, type 5C is associated with mutations in the BSCL2 gene on chromosome 11.
BSCL2 is classified as a druggable target with score 10.4.
The phenotypic spectrum of BSCL2-related neurologic disorders includes Silver syndrome and variants of Charcot-Marie-Tooth disease type 2, distal hereditary motor neuropathy (dHMN) type V, and spastic paraplegia 17.
BSCL2-related neurologic disorders should be suspected in individuals with the following clinical and electrophysiologic features.
Clinical features
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
No approved treatments are currently available for neuronopathy, distal hereditary motor, type 5C. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with BSCL2-related neurologic disorders, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Annual neurologic evaluation of gait, strength, muscular atrophy, and deep tendon reflexes by a neurologist is appropriate.
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Phenotype severity distribution: 3 always present features.
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:01 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Brain and nerves
2 |
Difficulty walking (gait disturbance), Babinski sign |
Arms and legs | 2 | Distal lower limb muscle weakness, Distal lower limb amyotrophy |
Age of onset: adulthood.
BSCL2-related neurologic disorders affect both the lower and upper motor neurons. Detailed clinical and electrophysiologic studies in 90 individuals with the pathogenic variant showed incomplete penetrance, clinical intrafamilial variability with several phenotypic subtypes being reported (even within the same family), and broad variation in disease severity, suggesting a subdivision into the following six main phenotypes (subtypes 1-6), all of which can be seen in the same family . Subtype 1. No signs or symptoms. No clinical or electrophysiologic abnormalities are present. Subtype 2. Clinical signs but no symptoms. Suggestive clinical signs include foot deformity, mild asymmetric thenar wasting, brisk lower-limb deep-tendon reflexes (DTRs), and/or electrophysiologic abnormalities.
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Individuals with the BSCL2 pathogenic missense variant (in which the amino acid asparagine required for N-glycosylation is exchanged) usually remain ambulatory and active up to old age. In many individuals, the phenotype is dominated by subtypes 2, 3, or 5 . Individuals with the BSCL2 pathogenic variant exhibit more severe phenotypes (subtypes 4 and 6). Some of these individuals may become wheelchair bound during the second decade . Pathogenic variant , which disrupts the N-glycosylation motif, was identified in affected individuals from a Korean family with autosomal dominant CMT type 2. These individuals had predominant hand involvement, pyramidal signs, and sensory loss.
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Reduced penetrance for BSCL2-related neurologic disorders has been shown by and . A detailed genotype-phenotype correlation study in 90 individuals with the pathogenic variant demonstrated that 24.4% of individuals with the variant remained asymptomatic (subtype 1) or were only subclinically affected (subtype 2) .
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Hereditary disorders to consider in the differential diagnosis for subtypes of BSCL2-related neurologic disorder. Other types of axonal neuropathies (see Charcot-Marie-Tooth Hereditary Neuropathy Overview), variants of amyotrophic lateral sclerosis (ALS), or hereditary spastic paraplegia may mimic BSCL2-related neurologic disorder subtypes:
Subtype 3.
GARS1-associated axonal neuropathy caused by pathogenic variants in GARS1 and inherited in an autosomal dominant manner
• Subtype 4
ALS4 (juvenile-onset motor neuron disease) caused by pathogenic variants in SETX and inherited in an autosomal dominant manner (See ALS Overview.)
SPG3A, caused by pathogenic variants in ATL1 and typically inherited in an autosomal dominant manner
• Subtype 5
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Genetic testing for BSCL2 is available. Testing is considered confirmatory for diagnosis.
EMG with NCV
Complete family history
Consultation with a clinical geneticist and/or genetic counselor
Treatment remains symptomatic and affected individuals are often evaluated and managed by a multidisciplinary team that includes neurologists, physiatrists, orthopedic surgeons, clinical geneticists, and physical and occupational therapists. Physiotherapy is appropriate. Orthopedic treatment includes orthopedic shoes and calipers (polypropylene devices that fit between the thighs and hold the legs and hips in a balanced position for standing, used in conjunction with crutches or a walker) to stabilize gait. Foot deformities are corrected surgically.
Early regular physiotherapy can prevent contractures to a certain extent.
Annual neurologic evaluation of gait, strength, muscular atrophy, and deep tendon reflexes by a neurologist is appropriate.
See for issues related to testing of at-risk relatives for genetic counseling purposes.
Search ClinicalTrials.gov i...
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "BSCL2-Related Neurologic Disorders/ Seipinopathy"
View trials for neuronopathy, distal hereditary motor, type 5C